Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals SPPI
report update icon

Quarterly report 2023-Q1
added 11-21-2026

Spectrum Pharmaceuticals Book Value | SPPI

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.
What is included in book value
  • Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
  • Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
Features of the metric
  • Assessment of the company's "real" value
    Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
  • Comparison with market capitalization
    Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
  • Indicator of financial stability
    If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
  • Key component for financial ratios
    Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Spectrum Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
27.9 M 47.6 M 134 M 190 M 271 M 351 M 236 M 213 M 255 M 282 M 289 M 188 M 74.5 M - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
351 M 27.9 M 197 M

Quarterly Book Value Spectrum Pharmaceuticals

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
26.8 M 27.9 M 35.9 M 33.4 M 55.3 M 47.6 M 79.5 M 109 M 122 M 134 M 168 M 131 M 154 M 190 M 235 M 255 M 273 M 271 M 287 M 344 M 324 M 351 M 305 M 199 M 217 M 236 M 251 M 236 M 208 M 213 M 215 M 234 M 230 M 255 M 257 M 266 M 266 M 282 M 302 M 278 M 284 M 289 M 280 M 263 M 239 M 188 M 174 M 114 M 188 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
351 M 26.8 M 207 M

Book Value of other stocks in the Biotechnology industry

Issuer Book Value Price % 24h Market Cap Country
Exelixis Exelixis
EXEL
2.16 B $ 64.59 -1.88 % $ 17.5 B usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
35.5 M $ 13.09 -2.68 % $ 374 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
45.4 M $ 0.85 -4.67 % $ 56.8 M usaUSA
BioNTech SE BioNTech SE
BNTX
19.2 B $ 80.87 -0.63 % $ 19.5 B germanyGermany
Alkermes plc Alkermes plc
ALKS
1.82 B $ 44.89 -2.79 % $ 7.39 B irlandaIrlanda
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
541 M $ 68.6 -0.77 % $ 1.38 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
-9.78 M $ 0.11 -7.75 % $ 178 K usaUSA
AC Immune SA AC Immune SA
ACIU
44.9 M $ 1.98 -7.28 % $ 199 M schweizSchweiz
Atara Biotherapeutics Atara Biotherapeutics
ATRA
-38.5 M $ 6.51 2.6 % $ 81.7 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
293 M $ 0.63 -5.62 % $ 139 M usaUSA
Altimmune Altimmune
ALT
225 M $ 1.33 -6.03 % $ 117 M usaUSA
AnaptysBio AnaptysBio
ANAB
317 M $ 46.65 -1.58 % $ 1.35 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
2.33 B - -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-163 M $ 252.39 -1.39 % $ 15.3 B danmarkDanmark
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
214 M $ 7.42 -2.37 % $ 203 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
581 M $ 14.7 -1.28 % $ 1.98 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
178 M $ 0.91 -6.96 % $ 242 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
275 M $ 3.97 0.89 % $ 324 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
88.3 M $ 129.32 -4.69 % $ 6.43 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
-2.08 B $ 75.96 -2.84 % $ 14.5 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
-119 M $ 7.23 -1.3 % $ 1.52 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
610 M $ 2.89 -5.25 % $ 200 M britainBritain
Benitec Biopharma Benitec Biopharma
BNTC
177 M $ 7.95 -2.4 % $ 370 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
61.4 M $ 8.24 2.74 % $ 387 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
739 M $ 141.06 -2.35 % $ 28.1 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
699 M $ 6.9 -5.61 % $ 2.47 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
6.08 M $ 4.64 17.17 % $ 56.6 M israelIsrael
InMed Pharmaceuticals InMed Pharmaceuticals
INM
1.08 M $ 15.56 13.57 % $ 64.8 M canadaCanada
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
-683 M $ 12.36 -9.55 % $ 799 M usaUSA
Immutep Limited Immutep Limited
IMMP
144 M $ 3.11 -9.06 % $ 4.53 B australiaAustralia
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
11.7 B $ 228.26 -3.46 % $ 13.9 B irlandaIrlanda
BeyondSpring BeyondSpring
BYSI
-24 M $ 0.33 -24.42 % $ 13.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
112 M $ 0.94 -7.24 % $ 94.5 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
81.5 B $ 270.2 1.18 % $ 650 B usaUSA
Cue Biopharma Cue Biopharma
CUE
26.4 M $ 4.2 -6.67 % $ 398 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
257 M $ 2.49 1.84 % $ 206 M usaUSA
Codexis Codexis
CDXS
50.5 M $ 1.0 -5.17 % $ 87.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
379 M $ 7.75 -1.02 % $ 447 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
157 M $ 1.83 -2.66 % $ 171 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
61 M $ 0.37 -4.06 % $ 43.3 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
-219 M $ 3.06 2.68 % $ 111 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
527 M $ 27.36 -2.15 % $ 1.82 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
75.9 M $ 0.9 -9.7 % $ 90.3 M franceFrance
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
43.3 M $ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
13.5 M $ 2.01 -7.59 % $ 11.4 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
112 B $ 1 345.4 -0.44 % $ 1.21 T usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
302 M $ 24.73 -1.9 % $ 783 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
12 M $ 0.32 1.02 % $ 2.52 M israelIsrael
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
148 M $ 2.05 -15.81 % $ 27.3 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
61 M $ 76.99 0.03 % $ 997 M usaUSA